ArticleACR open rheumatology2026
Perceptions of Glucagon-like Peptide 1 Receptor Agonists Among Individuals With Knee Osteoarthritis and Excess Weight: A Qualitative Study.
Article in ACR open rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveGlucagon-like peptide 1 receptor agonists (GLP-1RAs) facilitate weight loss and reduce pain among individuals with knee osteoarthritis (OA). We investigated attitudes and barriers influencing GLP-1RA use among individuals with knee OA and excess weight to draw distinctions in perspectives between patients with and without GLP-1RA experience.
methodsIn this cross-sectional qualitative study guided by the Framework Analysis method, we conducted structured interviews with persons with knee OA and excess weight. The moderator's guide included questions about health, weight loss history, and thoughts and experiences related to GLP-1RAs. Of the 286 patients prescreened, 30 completed an interview, after which saturation was reached. Interview transcripts were coded by research assistants using Dedoose software, and themes were identified using inductive analysis, charting, and memo writing.
resultsThe 30 individuals interviewed were majority female and most self-identified as White. Fifteen participants had current or prior GL-P1RA use, and fifteen had never taken GLP-1RAs. We identified four major themes: (1) health care providers were the primary GLP-1RA information source; (2) most participants recognized that weight loss could contribute to knee pain relief; (3) "ever users" reported overall positive experiences and found GLPA-1RAs helped facilitate healthy lifestyle changes, whereas "never users" more often described medications as a last resort after lifestyle changes fail; and (4) cost was the most significant barrier to GLP-1RA use.
conclusionWe found that perceptions both differed and overlapped among participants with and without prior GLP-1RA use. Clinicians should address potential concerns regarding GLP-1RAs when discussing treatment options with patients with excess weight and knee OA.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.